EdgarLookup

TTM TECHNOLOGIES INC — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that TTM TECHNOLOGIES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
6.1%
Profit Margin
Net income ÷ revenue
4.6%
Return on Assets
Net income ÷ assets
+19%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $2.91B Feb 17, 2026
FY2025 Dec 30, 2024 $2.44B Feb 17, 2026
FY2025 Jan 1, 2024 $2.23B Feb 17, 2026

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $2.91B Feb 17, 2026
FY2025 Dec 30, 2024 $2.44B Feb 17, 2026
FY2025 Jan 1, 2024 $2.23B Feb 17, 2026
FY2024 Jan 2, 2023 $2.50B Feb 21, 2025
FY2024 Jan 3, 2022 $2.25B Feb 27, 2024
FY2023 Dec 28, 2020 $2.11B Mar 3, 2023
FY2021 Dec 30, 2019 $2.13B Mar 1, 2022
FY2020 Dec 31, 2018 $2.24B Feb 22, 2021
FY2019 Jan 1, 2018 $2.66B Feb 26, 2020
FY2018 Jan 2, 2017 $2.53B Feb 26, 2019

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $601.69M Feb 17, 2026
FY2025 Dec 30, 2024 $477.38M Feb 17, 2026
FY2025 Jan 1, 2024 $413.27M Feb 17, 2026
FY2024 Jan 2, 2023 $457.97M Feb 21, 2025
FY2024 Jan 3, 2022 $372.01M Feb 27, 2024
FY2023 Dec 28, 2020 $359.02M Mar 3, 2023
FY2021 Dec 30, 2019 $377.18M Mar 1, 2022
FY2020 Dec 31, 2018 $402.67M Feb 22, 2021
FY2019 Jan 1, 2018 $429.58M Feb 26, 2020
FY2018 Jan 2, 2017 $423.62M Feb 26, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $177.45M Feb 17, 2026
FY2025 Dec 30, 2024 $56.30M Feb 17, 2026
FY2025 Jan 1, 2024 ($18.72M) Feb 17, 2026
FY2024 Jan 2, 2023 $94.58M Feb 21, 2025
FY2024 Jan 3, 2022 $54.41M Feb 27, 2024
FY2023 Dec 28, 2020 $177.54M Mar 3, 2023
FY2021 Dec 30, 2019 $41.30M Mar 1, 2022
FY2020 Dec 31, 2018 $173.58M Feb 22, 2021
FY2019 Jan 1, 2018 $124.21M Feb 26, 2020
FY2018 Jan 2, 2017 $34.86M Feb 26, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $264.68M Feb 17, 2026
FY2025 Dec 30, 2024 $116.04M Feb 17, 2026
FY2025 Jan 1, 2024 $42.32M Feb 17, 2026
FY2024 Jan 2, 2023 $210.41M Feb 21, 2025
FY2024 Jan 3, 2022 $125.99M Feb 27, 2024
FY2023 Dec 28, 2020 $28.09M Mar 3, 2023
FY2021 Dec 30, 2019 $109.63M Mar 1, 2022
FY2020 Dec 31, 2018 $118.97M Feb 22, 2021
FY2019 Jan 1, 2018 $212.76M Feb 26, 2020
FY2018 Jan 2, 2017 $173.45M Feb 26, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $28.99M Feb 17, 2026
FY2025 Dec 30, 2024 $31.85M Feb 17, 2026
FY2025 Jan 1, 2024 $27.27M Feb 17, 2026
FY2024 Jan 2, 2023 $24.81M Feb 21, 2025
FY2024 Jan 3, 2022 $18.15M Feb 27, 2024
FY2023 Dec 28, 2020 $19.77M Mar 3, 2023
FY2021 Dec 30, 2019 $17.94M Mar 1, 2022
FY2020 Dec 31, 2018 $13.72M Feb 22, 2021

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $291.88M Feb 17, 2026
FY2025 Dec 30, 2024 $236.89M Feb 17, 2026
FY2025 Jan 1, 2024 $187.28M Feb 17, 2026
FY2024 Jan 2, 2023 $272.87M Feb 21, 2025
FY2024 Jan 3, 2022 $176.63M Feb 27, 2024
FY2023 Dec 28, 2020 $287.18M Mar 3, 2023
FY2021 Dec 30, 2019 $311.94M Mar 1, 2022
FY2020 Dec 31, 2018 $273.14M Feb 22, 2021
FY2019 Jan 1, 2018 $332.76M Feb 26, 2020
FY2018 Jan 2, 2017 $298.34M Feb 26, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $292.57M Feb 17, 2026
FY2025 Dec 30, 2024 $185.74M Feb 17, 2026
FY2025 Jan 1, 2024 $160.24M Feb 17, 2026
FY2024 Jan 2, 2023 $102.88M Feb 21, 2025
FY2024 Jan 3, 2022 $81.95M Feb 27, 2024
FY2023 Dec 28, 2020 $103.29M Mar 3, 2023
FY2021 Dec 30, 2019 $142.58M Mar 1, 2022
FY2020 Dec 31, 2018 $150.13M Feb 22, 2021
FY2019 Jan 1, 2018 $151.35M Feb 26, 2020
FY2018 Jan 2, 2017 $85.14M Feb 26, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $3.84B Feb 17, 2026
FY2025 Dec 30, 2024 $3.47B Feb 17, 2026
FY2024 Jan 1, 2024 $3.32B Feb 21, 2025
FY2024 Jan 2, 2023 $3.32B Feb 27, 2024
FY2023 Jan 3, 2022 $3.03B Mar 3, 2023
FY2021 Dec 28, 2020 $2.90B Mar 1, 2022
FY2020 Dec 30, 2019 $3.56B Feb 22, 2021
FY2019 Dec 31, 2018 $3.46B Feb 26, 2020
FY2019 Jan 1, 2018 $2.78B Feb 26, 2020
FY2018 Jan 2, 2017 $2.50B Feb 26, 2019

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $1.76B Feb 17, 2026
FY2025 Dec 30, 2024 $1.56B Feb 17, 2026
FY2025 Jan 1, 2024 $1.51B Feb 17, 2026
FY2025 Jan 2, 2023 $1.54B Feb 17, 2026
FY2024 Jan 3, 2022 $1.46B Feb 21, 2025
FY2024 Dec 28, 2020 $1.44B Feb 27, 2024
FY2023 Dec 30, 2019 $1.28B Mar 3, 2023
FY2021 Dec 31, 2018 $1.23B Mar 1, 2022
FY2020 Jan 1, 2018 $1.01B Feb 22, 2021
FY2017 Jan 2, 2017 $820.85M Feb 23, 2018

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $670.14M Feb 17, 2026
FY2025 Dec 30, 2024 $670.14M Feb 17, 2026
FY2024 Jan 1, 2024 $702.74M Feb 21, 2025
FY2024 Jan 2, 2023 $760.44M Feb 27, 2024
FY2023 Jan 3, 2022 $637.32M Mar 3, 2023
FY2021 Dec 28, 2020 $637.32M Mar 1, 2022
FY2021 Dec 30, 2019 $706.52M Mar 1, 2022
FY2020 Dec 31, 2018 $698.78M Feb 22, 2021
FY2019 Jan 1, 2018 $372.57M Feb 26, 2020
FY2018 Jan 2, 2017 $372.61M Feb 26, 2019

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $1.02B Feb 17, 2026
FY2025 Dec 30, 2024 $838.42M Feb 17, 2026
FY2024 Jan 1, 2024 $782.12M Feb 21, 2025
FY2024 Jan 2, 2023 $800.84M Feb 27, 2024
FY2023 Jan 3, 2022 $706.26M Mar 3, 2023
FY2021 Dec 28, 2020 $651.84M Mar 1, 2022
FY2020 Dec 30, 2019 $474.31M Feb 22, 2021
FY2019 Dec 31, 2018 $433.01M Feb 26, 2020
FY2018 Jan 1, 2018 $230.85M Feb 26, 2019
FY2017 Jan 2, 2017 $74.79M Feb 23, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $501.23M Feb 17, 2026
FY2025 Dec 30, 2024 $503.93M Feb 17, 2026
FY2024 Jan 1, 2024 $450.21M Feb 21, 2025
FY2024 Jan 2, 2023 $402.75M Feb 27, 2024
FY2023 Jan 3, 2022 $537.68M Mar 3, 2023
FY2021 Dec 28, 2020 $451.57M Mar 1, 2022
FY2020 Dec 30, 2019 $379.82M Feb 22, 2021
FY2019 Dec 31, 2018 $256.36M Feb 26, 2020
FY2018 Jan 1, 2018 $409.33M Feb 26, 2019
FY2018 Jan 2, 2017 $256.28M Feb 26, 2019

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 $916.15M Feb 17, 2026
FY2025 Dec 30, 2024 $918.15M Feb 17, 2026
FY2016 Jan 2, 2017 $1.02B Feb 24, 2017
FY2016 Dec 28, 2015 $1.17B Feb 24, 2017
FY2015 Dec 29, 2014 $502.69M Feb 25, 2016
FY2014 Dec 30, 2013 $370.01M Feb 27, 2015
FY2013 Dec 31, 2012 $400.01M Feb 21, 2014
FY2012 Dec 31, 2011 $338.25M Mar 1, 2013
FY2011 Dec 31, 2010 $380.12M Feb 29, 2012

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 1 Feb 17, 2026
FY2025 Dec 30, 2024 0 Feb 17, 2026
FY2025 Jan 1, 2024 0 Feb 17, 2026
FY2024 Jan 2, 2023 0 Feb 21, 2025
FY2024 Jan 3, 2022 0 Feb 27, 2024
FY2023 Dec 28, 2020 1 Mar 3, 2023
FY2021 Dec 30, 2019 0 Mar 1, 2022
FY2020 Dec 31, 2018 1 Feb 22, 2021
FY2019 Jan 1, 2018 1 Feb 26, 2020
FY2018 Jan 2, 2017 0 Feb 26, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 1 Feb 17, 2026
FY2025 Dec 30, 2024 0 Feb 17, 2026
FY2025 Jan 1, 2024 0 Feb 17, 2026
FY2024 Jan 2, 2023 0 Feb 21, 2025
FY2024 Jan 3, 2022 0 Feb 27, 2024
FY2023 Dec 28, 2020 1 Mar 3, 2023
FY2021 Dec 30, 2019 0 Mar 1, 2022
FY2020 Dec 31, 2018 1 Feb 22, 2021
FY2019 Jan 1, 2018 1 Feb 26, 2020
FY2018 Jan 2, 2017 0 Feb 26, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Dec 29, 2025 103.38M Feb 17, 2026
FY2025 Dec 30, 2024 102.00M Feb 17, 2026
FY2024 Jan 1, 2024 102.11M Feb 21, 2025
FY2024 Jan 2, 2023 102.23M Feb 27, 2024
FY2023 Jan 3, 2022 103.53M Mar 3, 2023
FY2021 Dec 28, 2020 106.77M Mar 1, 2022
FY2020 Dec 30, 2019 105.51M Feb 22, 2021
FY2019 Dec 31, 2018 103.69M Feb 26, 2020
FY2018 Jan 1, 2018 101.82M Feb 26, 2019
FY2017 Jan 2, 2017 100.40M Feb 23, 2018